<DOC>
	<DOCNO>NCT00702247</DOCNO>
	<brief_summary>To evaluate toxicity profile efficacy tandem autologous-nonmyeloablative transplant approach newly diagnose myeloma patient young 65 year</brief_summary>
	<brief_title>Tandem Autologous- Nonmyeloablative Allogeneic Transplant Newly Diagnosed Multiple Myeloma ( Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>DurieSalmon stage IIAIIIB multiple myeloma Age &gt; 18 â‰¤ 65 year Previously untreated myeloma Presence sibling ( potential donor ) Bilirubins &lt; twice normal ; ALAT ASAT &lt; four time normal Left ventricular ejection fraction &gt; 40 % Creatinine clearances &gt; 40 mL/min Pulmonary dysfunction diffuse capacity carbon monoxide ( DLCO ) &gt; 40 % and/or need continuous oxygen supplementation Karnofsky performance status &gt; 60 % Patients must give write informed consent Age &gt; 65 year Previously treat myeloma Absence sibling ( genetic randomisation apply ) Karnofsky performance status score &lt; 60 % HIVinfection Pregnancy Refusal use contraceptive technique 12 month follow treatment Patients unable give write informed consent PS . Informed consent obtain patient accord Institutional Review Boards participate center . The study conduct accord Declaration Helsinki .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Multiple Myeloma - Nonmyeloablative transplantation - Autologous Transplant - Graft versus myeloma</keyword>
	<keyword>Newly diagnose multiple myeloma</keyword>
	<keyword>Tandem Auto-Allo Transplant</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Event free survival</keyword>
	<keyword>Disease response</keyword>
</DOC>